Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Kronos cracks $105m series A
GV contributed to a round for MIT-founded small molecule cancer drug spinout Kronos Bio, adding to $18m raised by the latter 14 months ago.
Recursion reconciles $121m
The series C for Utah-founded drug discovery platform creator Recursion included capital from University of Minnesota and Texas Tech University System.
Biontech completes $325m series B
Fidelity Management & Research has led a $325m series B round for Biontech, a spinout of Johannes Gutenberg University Mainz whose backers also include Sanofi and Pfizer.
Revolution celebrates $100m
Third Rock contributed to a $100m series C round for UIC's cancer drug developer Revolution that brought its total to $226m.
Tier IV tears it up to raise $105m
Sompo Japan Nipponkoa led the Utec-backed autonomous vehicle software developer's series A round, which included Yamaha Motor, Aisan Technology and existing investor KDDI.
Bayer leads Century to $250m
Immuno-oncology therapy developer Century Therapeutics has emerged from stealth, having been established by Versant Ventures to advance Stanford and Harvard research.
CFS sparks $115m series A close
Just over a year after securing an initial $50m tranche backed by Eni, MIT’s Commonwealth Fusion Systems has closed its series A round with $115m in capital.
CureFit stretches to $120m in Unilever-backed round
CureFit had held discussions with SoftBank Vision Fund over a $200m investment, but Unilever Ventures has instead stepped up as part of a $120m round.

Other News

CureFit starts training for $200m round
SoftBank is reportedly considering an investment of between $200m and $350m in CureFit, whose existing investors include the University of California-backed UC-RNT Fund.
Thrive Earlier Detection identifies $110m series A
Thrive will commercialise a blood test for multiple early-stage cancers based on research at Johns Hopkins University, following a series A round backed by Blue Cross and Blue Shield Association.
AlloVir secures $120m funding allocation
The T-Cell therapy developer, based on research at Baylor College of Medicine, has received funding in a Gilead Sciences-backed series B round led by Fidelity Management and Research.
GetYourGuide goes to $484m series E
ETH Zurich spinout GetYourGuide secured $484m in a round led by SoftBank Vision Fund that took its total funding past $650m.
Zipline speeds up with $190m
Stanford-backed medical supplies delivery service Zipline has revealed two funding rounds totaling $190m, one of which is a $70m series C that included existing backer GV.
Byton moves closer to $500m series C
FAW Group will reportedly provide $100m for TUS Holdings-backed Byton for a $500m round likely to value the electric SUV developer at more than $2.5bn.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg